US 8,945,546 B2 · IP-10 antibodies and their uses

Abstract

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.

Claims21

Dependent claims

A method of inhibiting an inflammatory or autoimmune response mediated by activated T cells or NK cells, comprising contacting the T cells or NK cells with an antibody, or antigen-binding portion thereof, which specifically binds IP-10 (SEQ ID NO:

121), such that the inflammatory or autoimmune response is inhibited, wherein the antibody or antigen-binding portion thereof:
(a) comprises heavy chain variable region CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs:
5, 17, and 28, respectively, and light chain variable region CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs:
55, 66, and 77, respectively;
(b) comprises heavy and light chain variable region sequences comprising SEQ ID NOs:
39 and 88, respectively;
or
(c) binds an epitope on human IP-10 (SEQ ID NO:
121) recognized by a reference antibody, wherein the reference antibody comprises heavy and light chain variable region sequences as set forth in SEQ ID NOs:
39 and 88, respectively.

7 more elements

A method of treating an inflammatory or autoimmune disease in a subject, comprising administering to the subject an antibody, or antigen-binding portion thereof, which specifically binds IP-10 (SEQ ID NO:

121), wherein the antibody or antigen-binding portion thereof:
(a) comprises heavy chain variable region CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs:
5, 17, and 28, respectively, and light chain variable region CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs:
55, 66, and 77, respectively;
(b) comprises heavy and light chain variable region sequences comprising SEQ ID NOs:
39 and 88, respectively;
or
(c) binds an epitope on human IP-10 (SEQ ID NO:
121) recognized by a reference antibody, wherein the reference antibody comprises heavy and light chain variable region sequences as set forth in SEQ ID NOs:
39 and 88, respectively.

7 more elements

Dependencies are inferred from the claim text.

Facts

Application

13/478,786Filed 23 May 2012 · division

Priority

10 Dec 2003

Published

US 2012/0230998 A113 Sep 2012

Granted

3 Feb 2015

Term ends

Not estimatedThe source records don’t support an estimate.

Classification43 codes

C07K 16/24
Against material from animals or humans: against cytokines, lymphokines or interferons
A61P 1/00
Drugs for disorders of the alimentary tract or the digestive system
A61P 1/02
Drugs for disorders of the alimentary tract or the digestive system: stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…

Family

Application60/529,180Us provisional application · filed 10 Dec 2003

Application11/009,731Parent of this continuation · filed 10 Dec 2004

Application12/472,877Parent of this division · filed 27 May 2009

US 2012/0230998 A1Pre-grant publication · published 13 Sep 2012

US 8,258,266 B2Parent of this division

Application12/472,877Parent of this continuation

US 2005/0191293 A1Published application

US 2010/0077497 A1Published application

US 8,945,546 B2This patent

From the US filing history. Foreign family members aren’t listed.

IP-10 antibodies and their uses

Life of this patent

IP-10 antibodies and their uses

Life of this patent

Abstract

Claims21